News & Events

25 Jul

FDA Accelerated Approval Open for FSHD Agent Del-Brax, With Newly Initiated Phase 3 Study to Confirm Efficacy

Story originally appeared on neurologylive.com In a number of company updates, Avidity Biosciences announced the FDA’s openness for an accelerated approval for its investigational agent delpacibart braxlosiran (del-brax) as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD). The company has also initiated its phase 3 FORWARD...

04:33 / FSHD News / News

12 Jul

Avidity Shares Promising Interim Data from its FORTITUDE Trial

By Justin Cohen, PhD Avidity Biosciences recently announced exciting interim results from their randomized, double-blind, placebo-controlled Phase 1/2 FORTITUDE trial in facioscapulohumeral muscular dystrophy (FSHD). Termed delpacibart braxlosiran or del-brax for short, this first-in-class therapy is a muscle targeting antibody bound to a payload that targets...

04:47 / Justin's Blog

30 Jun

FSHD treatment del-brax (formerly AOC 1020) aids muscle function

Read original article here. by Margarida Maia, PhD | June 20, 2024 AOC 1020, an investigational treatment by Avidity Biosciences that’s now called delpacibart braxlosiran, or del-brax, helped adults with facioscapulohumeral muscular dystrophy (FSHD) grow stronger muscles and extend their arms farther than they could four months earlier. These are early data from FORTITUDE (NCT05747924), a...

03:23 / FSHD News / FSHD Story / News

05 Jun

Chris Carrino heads to Capitol Hill to advocate for FSHD

On May 8, 2024, Chris and Laura Carrino joined with members of the FSHD Society for a trip to Capitol Hill to meet with Senators, Congressman, and staffers in an effort to advocate for FSHD. With promising clinical trials underway, there is an urgency to introduce...

03:19 / Foundation News

08 Jul

Hope for the Future of Muscular Dystrophy Treatment: Kate Therapeutics Harnesses their myoAAV Technology for FSHD

By Justin Cohen, PhD Kate Therapeutics, a San Diego base biotechnology company has announced funding to advance their muscle and cardiovascular disease portfolio. Among the first diseases to be explored is Facioscapulohumeral muscular dystrophy (FSHD), exciting news for patients like myself and their families who are impacted from this...

09:00 / Justin's Blog

30 Jun

Breaking Barriers in the Sky: The Future of Air-Travel for Wheelchair Users

By Justin Cohen, PhD Air-travel for wheelchair users come with a unique set of challenges that cause many to forgo the plane altogether. This could all change after the recent Aircraft Interiors Expo in Hamburg, Germany, which unveiled a new airplane seat prototype that could revolutionize air-travel for...

09:00 / Justin's Blog

12 Apr

WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent neuromuscular disorders. The disease is linked to copy number reduction and/or epigenetic alterations of the D4Z4 macrosatellite on chromosome 4q35 and associated with aberrant gain of expression of the transcription factor DUX4, which triggers a...

13:27 / FSHD News

12 Feb

Brooklyn Nets’ radio announcer Chris Carrino honored by NBA

Read original article and view video content here. Brooklyn Nets' radio announcer Chris Carrino is being honored by the NBA for both his decades of work and the obstacles he has overcome. After more than 20 years as the radio play-by-play voice of the Nets, Carrino has...

06:26 / Foundation News / News

16 Jan

NBA honors Chris Carrino with ‘Values of the Game’ award

This article originally appeared on netsdaily.com. The NBA is honoring Chris Carrino, the play-by-play announcer, with the prestigious NBA Values of the Game Award this year, the Nets and the league reported Tuesday. The award recognizes an individual at an NBA team who exemplifies the values of the...

06:52 / Foundation News / News

01 Aug

First Participant With FSHD Dosed in Phase 3 Study of Losmapimod

“The progression of FSHD can make it increasingly difficult to pursue work, hobbies, social and family life,” Mark Stone, CEO of the FSHD Society, said. “The REACH trial with losmapimod represents the first real hope for those living with the disease, their families and their caregivers,...

03:33 / FSHD News / News